A bioadhesive extruded single or multi-layered thin film, especially useful in intra-oral controlled-releasing delivery, having a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of 40-95 20-92% by weight of a hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer such as ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a medicament, e.g. anesthetics, analgesics, anticaries agents, anti-inflammatories, antihistamines, antibiotics, antibacterials, fungistats, etc.
|
1. A pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of 40-9520-93% by weight of a hydroxypropyl cellulose having a molecular weight above 100,000, 5-60% of a homopolymer of ethylene oxide having a molecular weight from 3,000,000 to 5,000,000, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.
2. The extruded film of
3. The extruded film of
4. The extruded film of
5. The extruded film of
6. The extruded multi-layer film of
7. The extruded film of
8. The extruded multi-layer film of
9. The extruded multi-layer film of
|
1. Field of the Invention
The present invention relates to a controlled-releasing medicament-containing preparation for intra-oral use, and is more especially concerned with such a preparation (and the process of using it) in the form of a very thin extruded thermoplastic film (which can be in single layer or laminated multi-layer form) having at least one bioadhesive layer containing 40-9520-93% of a thermoplastic cellulose ether and 5-60% of a homopolymer of ethylene oxide which can adhere to the mucosa of the oral cavity. The extruded film drug delivery system of the present invention, which has incorporated therein the medicament to be dispensed, is so thin and flexible when wet as to be unobtrusive to the patient after it has been properly positioned and placed in the mouth.
2. Description of the Prior Art
Several systems have previously been described which pertain to the delivery of drugs into the oral cavity. These include:
1. Treatment of periodontal disease with tetracycline, chlorhexidine or metronidazole loaded into hollow cellulose acetate fibers. These fibers are packed in the periodontal pockets and provide controlled release of the drug to the infected area.
2. Cast films containing ethyl cellulose/propylene glycol with chlorhexidine or metronidazole for treatment of periodontal disease.
3. An orthodontic appliance with a hydroxyethyl methacrylate/methyl methacrylate copolymer (HEMA/MMA) matrix. Sodium fluoride is incorporated into the HEMA/MMA matrix to provide sustained fluoride release and enhanced anticaries activity. HEMA/MMA with fluoride may also be attached to the tooth in the form of a wafer-like tablet.
4. Silicone/ethyl cellulose/polyethylene glycol films containing sodium fluoride are applied as coatings on orthodontic bands or in chewing gum. Controlled release of fluoride and anticaries activity is claimed. The above systems are discussed in the "The Compendium of Continuing Education" Vol VI, No. 1, January 1985 p. 27-36 review article "Controlled Drug Delivery: A New Means of Treatment of Dental Disease", by J. Max Goodson, D.D.S., Ph.D. of the Forsyth Dental Center. Other systems, described in GB patent application No. 2,042,888 and U.S. Pat. Nos. 4,292,299/4,226,848 (Teijin Ltd., Japan), use combinations of cellulosic and polyacrylate polymers. The preferred materials are hydroxypropyl cellulose ("Klucel") and a copolymer of acrylic acid ("Carbopol") that is administered in the form of thin tablets (discs), granules or powder. Other polymers that might be added are vinyl copolymers, polysaccharides, gelatin and collagen. U.S. Pat. No. 4,517,173 (Nippon Soda Co. Ltd, Japan) uses various celluloses in a multi-layered non-extruded cast film preparation.
Examples of prior art products currently on the market include ointments such as ORABASE* with Benzocaine (Squibb), Kenalog* (Triamcinolone Acetonide) in ORABASE* (Squibb) and Mycostatin* (Nystatin) ointment (Squibb).
The prior art products and delivery systems described above are useful but have the following disadvantages:
Tablets, appliances, hollow fibers are "bulky" in the mouth, are difficult to keep in place and inconvenient to apply.
Ethyl cellulose and/or silicone films do not adhere to mucosal tissue.
Ointments (i.e., ORABASE*) have an unpleasant feel and do not last very long.
Except for ORABASE*, all the foregoing systems require professional application to the tooth or periodontal pockets.
The bioadhesive film of the present invention alleviates many of the above problems. It may be applied easily by the consumer. It has very little or no mouthfeel, it has good adhesion to the mucosal tissues, and provides controlled release of the medicament.
It is an object of this invention to provide an extruded film that is an effective and convenient intra-oral drug delivery system and method for applying and delivering controlled dosages of therapeutic agents into the oral cavity. This technology may also be extended for controlled drug delivery in skin care, gynecological applications, wound care and like uses.
The invention involves a pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of 40-9520-93% by weight of hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.
The present invention is directed to an extruded single or multi-layered laminated thin (1-10 mils or 0.025-0.25 mm) film, composed of selected water soluble and/or insoluble polymers. Various therapeutic agents are incorporated into the film during manufacture which are useful for treatment of oral disorders (i.e., denture discomfort, caries, periodontal disease, aphthous ulcers, etc.).
The extruded film of the present invention must have at least one bioadhesive layer, but may also have a reservoir layer and/or an outer protective barrier membrane layer. The therapeutic agent may be incorporated into any or all of the layers. When properly formulated and fabricated, these films will adhere to wet mucosal surfaces, provide a protective barrier for injured tissue and deliver controlled/sustained dosages of medication to the infected areas. The film may be designed for localized drug delivery (i.e., the periodontal pocket, an aphthous lesion), or may allow diffusion of the drug into the oral cavity.
An example of a non-localized system would be the delivery of sodium fluoride for caries prevention. A single or laminated film with good adhesion to the tooth or mucosal tissue may be employed in which the fluoride release rates may be controlled by varying film solubilities and/or concentration of fluoride in a multi-layered film.
An example of a localized application of medication would be in the treatment of aphthous lesions. A laminated two layer film with benzocaine incorporated into the adhesive layer would directly contact the injured mucosa. The outer layer would consist of non-soluble/non-adhesive polymers that provide durability, protection and directs the delivery of benzocaine toward the lesion.
The film forming polymers that are useful in this invention are selected from pharmaceutical grade materials, or those that are considered generally regarded as safe (GRAS) as food additives. They include, hydroxypropyl cellulose, and polyethylene oxide homopolymers. Small amounts of other polymers, e.g., polyvinyl ether-maleic acid copolymers and the like may be used in small amounts as well, replacing a small portion of the other polymers. The above materials are either water soluble of swellable and are most useful in the bioadhesive layer of the film. Various non-soluble polymers may also be incorporated for modification of the film's permeability properties, such as ethyl cellulose, propyl cellulose, polyethylene, polypropylene and carboxymethylcellulose (free acid). By varying the ratios of the above polymers both the solubility and the adhesive properties of each layer of film may be controlled. Therefore, depending on the desired delivery rate, the type of disorder to be treated, the area to be treated and the medication being administered it is possible to custom design the film by selecting and blending various polymers. The final film product may also be fabricated into flexible tapes of varied thickness and width, "spots" of different sizes and shapes or other pre-shaped forms.
The medicaments and pharmaceutical agents set forth in the prior art discussed above may generally be delivered by the drug delivery system of the present invention. Usable medicaments are those which are capable of withstanding the heats and pressures generated in the extrusion process involved in making the film of the present invention. Preferred medicaments include:
Anesthetics/Analgesics-benzocaine, dyclonine HCl, phenol, aspirin, phenacetin, acetaminophen, potassium nitrate, etc.
Anticaries Agents-sodium fluoride, sodium monofluorophosphate, stannous fluoride, etc.
Anti-inflammatories-hydrocortisone acetate, triamcinolone acetonide, dipotassium, glycyrrhizinate, etc.
Antihistamines-chlorpheniramine maleate, ephedrine HCL, diphenhydramine HCL, etc.
Antibiotics-i.e., tetracycline, doxycycline hyclate, meclocycline, minocycline, etc.
Antibacterials-chlorhexidine, cetyl pyridinium chloride, benzethonium chloride, dequalinium chloride, silver sulfadiazene, phenol, thymol, hexedine, hexetidine, alexidine, etc.
Fungistats-nystatin, miconazole, ketoconazole, etc.
The above are illustrative examples of therapeutic agents that are used to treat oral disorders. The present invention is not to be limited to these specific materials especially where it is intended to deliver drug outside of the oral cavity e.g. to skin where other drugs may be desirable.
The film of the present invention has the advantage of being an extruded film, rather than a cast film. When a multi-layered film is involved, the different layers can be coextruded and then laminated together, or else each layer can be separately extruded one on the other, and then laminated together, so that the final multi-layered film is still very thin. The films of the present invention can be made in thicknesses of only 1-10 mils or 0.025-0.25 mm. The films are so thin that when placed in the mouth after they become wet they soon become unobtrusive, and hardly noticeable by most patients.
The film must always have a bioadhesive layer, which enables it to adhere to wet mucosal surfaces. The bioadhesive layer has 40-9520-93% of hydroxypropyl cellulose, 5-60% of a homopolymer of ethylene oxide and 2-10% of a glycol plasticizer (all percents are % by weight).
The Hydroxypropyl cellulose (HPC), useful for purposes of the present invention is commercially available from Hercules, Inc. (Wilmington, DE) under the tradename KLUCEL*. Preferred grades include Klucel MF, with a molecular weight around 600,000 and having a viscosity of 4,000-6,000 cps (Brookfield) in 2 percent water solutions, or Klucel HF, having a molecular weight around 1,000,000 and viscosity of 1500-2500 cps in 1 percent water solution. In general, any HPC having a Molecular Weight above about 100,000 is useful for purposes of this invention.
The homopolymer of ethylene oxide useful for purposes of the present invention has a relatively high molecular weight, i.e., above 100,000 and preferably above 3,000,000. Such polymers are commercially available from various sources. The Union Carbide Corporation material, "Polyox WSR-301", which has a molecular weight of approximately 4,000,000-5,000,000 is most preferred for purposes of the present invention.
The "plasticizer" useful for purposes of the present invention are selected from glycols such as propylene glycol and polyethylene glycol; polyhydric alcohols such as glycerin and sorbitol; glycerol esters such as glycerol triacetate; fatty acid triglycerides such as NEOBEE* M-5 and MYVEROLS*; mineral oil; vegetable oils such as castor oil, etc.
For the uses for the present invention contemplated here, the plasticizer should be non-toxic. The purpose of the plasticizer is to improve polymer melt processing by reducing the polymer melt viscosity and to impart flexibility to the final product.
The preferred plasticizer for use in the present invention is either propylene glycol or polyethylene glycol (such as is available from Union Carbide Corporation as their series of Carbowaxes which runs from 200 to 600 molecular weight, of which we prefer to use Carbowax 400, which has a molecular weight of 400, average.
In addition to the polymers and plasticizer which are required ingredients of the films of the present invention, minor amounts of other non-essential but customary ingredients will often be used if desired, e.g., antioxidants, preservatives, flavors, colorants.
The following examples will serve to illustrate the present invention in greater detail. The units shown in the examples are parts by weight. The thickness of the layers is expressed in either mils (0.001 inches) or millimeters. For easy conversion, 4 mils is approximately equal to 0.1 mm.
Triple Layered Laminate Containing Sodium Fluoride for Anticaries Protection
This three layered film laminate is comprised of a "bioadhesive" layer, a sodium fluoride "reservoir" layer and, an "outer protective barrier membrane" layer, in which the composition and thickness of each layer are as shown below:
______________________________________ |
Outer |
Protective |
Bio- % w/w Barrier |
adhesive Reservoir Membrane |
Layer Layer Layer |
(4 mils) (1 mil) (1 mil) |
Ingredients (0.1 mm) (0.025 mm) |
(0.025 mm) |
______________________________________ |
Polyethylene oxide |
60.0 -- -- |
homopolymer (Unison |
Carbide-Polyox* WSR-301) |
Hydroxypropyl Cellulose |
30.0 20.0 24.0 |
(Hercules, Inc.-Klucel* MF) |
Polyethylene (Allied |
5.0 -- -- |
Chemical-6A) |
(Low Density) |
Propylene Glycol, U.S.P. |
3.0 -- -- |
Polyethylene Glycol |
2.0 -- -- |
400 (Union Carbide) |
Ethyl Cellulose (Hercules, |
-- 59.0 69.6 |
Inc.-N100F) |
Caprylic/Capric -- 5.0 6.0 |
Triglyceride(PVO |
Incorporated-Neobee M-5) |
Sodium Fluoride, U.S.P. |
-- 16.0 0.4 |
100.0 100.0 100.0 |
______________________________________ |
The process used to make the above laminate was:
a. Powder Blending-Each layer is made separately and all ingredients used therein except propylene glycol and Neobee M-5 (liquid plasticizers) are placed in a Patterson Kelley (PK) V-blender equipped with liquid addition capabilities. The ingredients which are all powders are blended for approximately 10-15 minutes while the liquid plasticizer is slowly added to the mix. Three separate powder blends are made, one for each layer.
b. Extrusion Process-A standard Johnson 2-1/2 inch vinyl/polyolefin extruder equipped with a single three stage screw was used to extrude the "powder blend". The temperature conditions for the water soluble powders are however quite different from those used for vinyls and polyolefins. The temperature (°C.) profile for the "reservoir" and "membrane layers" of the triple laminate was as follows:
______________________________________ |
Barrel Zone 1 |
100 |
Barrel Zone 2 |
125 |
Barrel Zone 3 |
135 |
Barrel Zone 4 |
145 |
Barrel Zone 5 |
160 |
Barrel Zone 6 |
170 |
Adapter 180 |
Die Zone 1 |
180 |
Die Zone 2 |
180 |
Die Zone 3 |
180 |
______________________________________ |
The films which had a width of 18 inches, were extruded at approximately 20 feet/minute through a flat lipped die. The temperature profile for the "bioadhesive layer" was:
______________________________________ |
Barrel Zone 1 |
125 |
Barrel Zone 2 |
140 |
Barrel Zone 3 |
165 |
Barrel Zone 4 |
170 |
Barrel Zone 5 |
185 |
Barrel Zone 6 |
185 |
Adapter 185 |
Die Zone 1 |
185 |
Die Zone 2 |
185 |
Die Zone 3 |
185 |
______________________________________ |
Each layer is extruded separately with the first layer extruded as a "free film". Successive layers are extruded onto each other and laminated by passing them through heated stainless steel rollers.
Test Results:
In vitro fluoride ion release studies were conducted on samples of the above described triple laminate film measuring 0.5 cm×1.25 cm (0.625 cm2) according to the following procedures:
The test sample is adhered to a glass slide by prewetting the film and placing the bioadhesive layer on the glass surface. The slide is then immersed in a beaker containing 100 ml of distilled water with continuous stirring. Five milliliter aliquots are withdrawn from the solution, at prescribed time intervals, and analyzed for fluoride content with an Orion Ionanalyzer equipped with a fluoride specific electrode. Release rates are then calculated from the data.
The results obtained indicated fluoride release rates in the order of 0.05-0.2 mgs/cm2 /hr for 24 hours. This falls within the desired range for maintaining constant low levels of fluoride in the mouth and enhanced anticaries activity. Release rates may be tailored to desired use levels by modification of the film composition and construction.
Single Layer Adhesive Film Containing Hydrocortisone Acetate (0.5%) As An Anti-Inflammatory Agent
The composition of the film, which was 0.1 mm. thick, was as follows:
______________________________________ |
Ingredients % w/w |
______________________________________ |
Ethylene Oxide Homopolymer |
59.4 |
(Polyox* WSR-301) |
Hydroxypropyl Cellulose |
30.0 |
(Klucel* MF) |
Polyethylene (AC-6A) 5.0 |
Propylene Glycol 3.0 |
Polyethylene Glycol 400 |
2.0 |
Butylated Hydroxy Toluene (BHT) |
0.1 |
FCC (preservative) |
Hydrocortisone Acetate |
0.5 |
100.0 |
______________________________________ |
The powder blending process and extruder conditions used were the same as those described in Example I for the "bioadhesive layer" of the sodium fluoride trilaminate. In vitro tests were performed on the above film and demonstrated a prolonged drug release pattern.
Single Layer Adhesive Film Containing Triamcinolone Acetonide (0.1%) As An Anti-Inflammatory
The composition of the film, which was 0.1 mm. thick, was as follows:
______________________________________ |
Ingredients % w/w |
______________________________________ |
Ethylene Oxide Homopolymer |
59.9 |
(Polyox WSR-301) |
Hydroxypropyl Cellulose |
29.9 |
(Klucel MF) |
Polyethylene (AC-6A) 5.0 |
Propylene Glycol 3.0 |
Polyethylene Glycol 400 |
2.0 |
BHT 0.1 |
Triamcinolone Acetonide |
0.1 |
100.0 |
______________________________________ |
The powder blending process and extruder conditions used to make the film of this Example 3 were the same as those of the "bioadhesive layer" of Example I.
Other desired active medicament ingredients may be incorporated into the adhesive films of any of Examples 1-3 in place of the particular medicament used in said examples. These include Benzocaine (analgesic), Potassium nitrate (analgesic), Silver sulfadiazene (antimicrobial),
Chlorhexidine (antimicrobial), miconazole nitrate (antifungal), Benzethonium chloride (antimicrobial), Tetracycline (antibiotic) and other similar therapeutic compounds.
Analgesic Films with Potassium Nitrate
This example shows 5 variations of the film having different solubilities, resulting in different release rates.
______________________________________ |
% w/w |
Ingredients 1 2 3 4 5 |
______________________________________ |
Polyethylene oxide |
23.75 57.00 55.00 |
55.00 57.00 |
homopolymer (Polyox* |
WSR-301) |
Hydroxypropyl Cell- |
68.30 -- -- -- -- |
ulose, N.F. (Klucel* HF) |
Hydroxypropyl Cell- |
-- 28.40 29.90 |
22.40 22.40 |
ulose, N.F. (Klucel* MF) |
Ethyl Cellulose -- 4.75 5.00 12.50 12.50 |
Polyethylene Glycol 400 |
1.90 1.90 2.00 2.00 2.00 |
Polyethylene Glycol 8000 |
0.95 -- -- -- -- |
Propylene Glycol, U.S.P. |
-- 2.85 3.00 3.00 3.00 |
BHT, F.C.C. 0.10 0.10 0.10 0.10 0.10 |
Potassium Nitrate, F.C.C. |
5.00 5.00 5.00 5.00 3.00 |
______________________________________ |
The above ingredients are blended in a Patterson-Kelly powder blender equipped with liquid addition capabilities. The resulting powder blend is then extruded into film on a Killion or Johnson vinyl extruder using processing procedures similar to those of the bioadhesive layer of Example I.
Anesthetic Films with Benzocaine (Laminate)
This is an example of a two-layer laminate. The processing conditions used were similar to those of the bioadhesive layer and outer protective barrier membrane layer of Example I.
______________________________________ |
A. Inner medicated bioadhesive layer |
Polyoxyethylene Homopolymer |
57.00 |
(Polyox* WSR-301) |
Hydroxypropyl Cellulose, N.F. |
28.40 |
(Klucel* MF) |
Polyethylene (AC-6A) 4.75 |
Propylene Glycol, U.S.P. |
2.85 |
Polyethylene Glycol 400 |
1.90 |
BHT, F.C.C. 0.10 |
Benzocaine, U.S.P. 5.00 |
100.00 |
B. Outer protective/barrier layer |
Hydroxypropyl Cellulose |
78.00 |
(Klucel* MF) |
Ethyl Cellulose 20.00 |
Polyethylene Glycol 400 |
2.00 |
100.00 |
______________________________________ |
Part A was extruded on a Johnson extruder followed by subsequent extrusion and lamination of Part B to A.
Samples were applied to oral lesions, and provided profound anesthetic effects (lasting several hours) within minutes of application.
The identical two-layer laminate may also be made by coextruding the inner medicated bioadhesive layer (Part A) and the outer protective barrier layer (Part B) through separate die slots within a coextruder and laminating the two layers together.
Anesthetic Films with Phenol and Dyclonine HCl
Four variations of a single layer bioadhesive film were made as shown below:
______________________________________ |
Ingredients 1 2 3 4 |
______________________________________ |
Polyethylene oxide homo- |
59.10 54.00 59.70 |
58.20 |
polymer (Polyox* WSR-301) |
Hydroxypropyl Cellulose |
29.45 26.91 29.75 |
29.00 |
(Klucel HF) |
Ethyl Cellulose 4.93 4.50 4.98 4.85 |
Propylene Glycol, U.S.P. |
2.96 2.70 2.99 2.91 |
Polyethylene Glycol 400 |
1.97 1.80 1.99 1.94 |
BHT, F.C.C. 0.09 0.09 0.09 0.10 |
Phenol, U.S.P. 1.50 -- -- -- |
Dyclonine HCl -- 10.00 0.50 3.00 |
______________________________________ |
Following the procedures for the bioadhesive layer of Example I, the powders were blended in P-K blender equipped with liquid addition capabilities. Resulting powders were extruded on a Killion laboratory-sized extruder.
Silver Sulfadiazene Films-Antimicrobial
Three different single-layered bioadhesive films containing 1.0% 0.5% and 0.5% respectively of silver sulfadiazene (SSD) were prepared on a heated Carver laboratory press (designed to simulate extruded conditions) as shown below.
______________________________________ |
% w/w |
Ingredients A B |
______________________________________ |
Polyethylene oxide homopolymer |
60.00 60.00 |
(Polyox* WSR-301) |
Hydroxypropyl Cellulose |
28.9 29.4 |
(Klucel* HF) |
Polyethylene (AC-6A) 5.0 5.0 |
Propylene Glycol, U.S.P. |
3.0 3.0 |
Polyethylene Glycol 400 |
2.0 2.0 |
BHT, F.C.C. 0.1 0.1 |
Silver Sulfadiazine 1.0 0.5 |
100.0 100.0 |
______________________________________ |
Effects on wound repair and activity against Staphylococcus aureus were evaluated in the guinea pig model. Full-thickness excisions were inoculated with 3.8×105 organisms, (Staph. aureus) and wound surface microbiology samples taken 10 minutes and 24 hours after treatment. Test films were placed on the wound and covered with BIOCLUSIVE* Transparent Dressings secured with elastic tape. Wound contraction was measured over an eight-day period using OPTOMAX* Computer-Assisted Image Analysis. The three films tested were the following:
A. 1.0% Silver Sulfadiazene, 125°C/2 minutes/4 tons
B. 0.5% Silver Sulfadiazene, 125°C/2 minutes/4 tons
C. 0.5% Silver Sulfadiazene, 150°C/3 minutes/4 tons
SILVADENE Cream and an untreated occluded control. The results indicated that:
1. SILVADENE* treated wounds significantly inhibited full-thickness wound contraction.
2. Film A, B and C inhibited wound contraction relative to that of BIOCLUSIVE* dressed wounds.
3. The three SSD films each permitted substantially faster wound contraction than that of wounds treated daily with SILVADENE* cream.
4. All films were very active against S. Aureus 24 hours after inoculation.
The films may be scaled up by using an extruder. This example demonstrates the feasibility of such a film to perform its intended purpose. Use of a press for larger samples would result in a non-uniform and lower-quality film than an extruded film.
Based on the above findings, the films were very effective antibacterial agents, while mildly inhibiting wound contraction. They offer clinicians a convenient and more effective delivery system for antimicrobials which can be place in wounds beneath any dressing or can be laminated to any acceptable dressing face.
Rubin, Howard, Perl, Martin M., Schiraldi, Michael T.
Patent | Priority | Assignee | Title |
10034833, | Aug 07 2009 | AQUESTIVE THERAPEUTICS, INC | Sublingual and buccal film compositions |
10058548, | Aug 06 2003 | GRÜNENTHAL GMBH | Abuse-proofed dosage form |
10064945, | May 11 2012 | Gruenenthal GmbH | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
10076498, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
10076499, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
10080721, | Jul 22 2009 | Gruenenthal GmbH | Hot-melt extruded pharmaceutical dosage form |
10111810, | Apr 11 2002 | AQUESTIVE THERAPEUTICS, INC | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
10130591, | Aug 06 2003 | GRÜNENTHAL GMBH | Abuse-proofed dosage form |
10154966, | May 29 2013 | GRÜNENTHAL GMBH | Tamper-resistant dosage form containing one or more particles |
10201502, | Jul 29 2011 | Gruenenthal GmbH | Tamper-resistant tablet providing immediate drug release |
10272607, | Oct 22 2010 | AQUESTIVE THERAPEUTICS, INC | Manufacturing of small film strips |
10285910, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Sublingual and buccal film compositions |
10285915, | Oct 17 2012 | The Procter & Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
10285916, | Oct 17 2012 | The Procter & Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
10300141, | Sep 02 2010 | GRÜNENTHAL GMBH | Tamper resistant dosage form comprising inorganic salt |
10334872, | Oct 11 2007 | PHILIP MORRIS PRODUCTS S.A. | Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet |
10335373, | Apr 18 2012 | Gruenenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
10335381, | May 08 2006 | University of Mississippi | Stabilized formulation of triamcinolone acetonide |
10369109, | Jun 17 2002 | GRÜNENTHAL GMBH | Abuse-proofed dosage form |
10449547, | Nov 26 2013 | GRÜNENTHAL GMBH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
10493016, | Sep 11 2002 | The Procter & Gamble Company | Tooth whitening product |
10493033, | Jul 22 2009 | GRÜNENTHAL GMBH | Oxidation-stabilized tamper-resistant dosage form |
10610528, | Dec 08 2009 | INTELGENX CORP | Solid oral film dosage forms and methods for making same |
10624862, | Jul 12 2013 | GRÜNENTHAL GMBH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
10675278, | Feb 04 2005 | GRÜNENTHAL GMBH | Crush resistant delayed-release dosage forms |
10695297, | Jul 29 2011 | GRÜNENTHAL GMBH | Tamper-resistant tablet providing immediate drug release |
10729658, | Feb 04 2005 | GRÜNENTHAL GMBH | Process for the production of an abuse-proofed dosage form |
10821074, | Aug 07 2009 | AQUESTIVE THERAPEUTICS, INC. | Sublingual and buccal film compositions |
10842750, | Sep 10 2015 | GRÜNENTHAL GMBH | Protecting oral overdose with abuse deterrent immediate release formulations |
10864164, | Jul 29 2011 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
10888499, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
10940626, | Oct 22 2010 | AQUESTIVE THERAPEUTICS, INC. | Manufacturing of small film strips |
11033374, | Aug 31 2007 | Ultradent Products, Inc. | Dental treatment devices comprising silicone-like elastomeric material |
11077068, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
11135216, | Aug 07 2009 | INDIVIOR UK LIMITED | Sublingual and buccal film compositions |
11160771, | May 05 2016 | AQUESTIVE THERAPEUTICS, INC | Enhanced delivery epinephrine compositions |
11191737, | May 05 2016 | AQUESTIVE THERAPEUTICS, INC | Enhanced delivery epinephrine compositions |
11207805, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC. | Process for manufacturing a resulting pharmaceutical film |
11213489, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
11224505, | Nov 02 2018 | JB&DH LIMITED PARTNERSHIP | Hybrid accommodating intraocular lens assemblages including discrete lens unit with segmented lens haptics |
11224576, | Dec 23 2004 | GRÜNENTHAL GMBH | Process for the production of an abuse-proofed dosage form |
11273131, | May 05 2016 | AQUESTIVE THERAPEUTICS, INC | Pharmaceutical compositions with enhanced permeation |
11298322, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
11304908, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
11304909, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
11452698, | Mar 15 2013 | Smith & Nephew, Inc. | Dissolvable gel-forming film for delivery of active agents |
11589980, | May 22 2016 | JB&DH LIMITED PARTNERSHIP | Hybrid accommodating intraocular lens assemblages |
11672757, | Jun 28 2017 | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | Hot melt extrusion for pharmaceutical vaginal film products |
11826472, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
11844865, | Jul 01 2004 | Grünenthal GmbH | Abuse-proofed oral dosage form |
11904055, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
4933182, | Mar 25 1986 | Rohto Pharmaceutical Co. Ltd. | Pharmaceutical composition for treating periodontal |
4997830, | Feb 07 1990 | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE, A CORP OF NEW YORK | Pharmaceutical composition for the treatment of periodontitis |
5064650, | Apr 19 1988 | Southwest Research Institute | Controlled-release salt sensitive capsule for oral use and adhesive system |
5112620, | Sep 20 1990 | The University of Mississippi | Polyethylene glycol ointment for apthous ulcers |
5114718, | Sep 20 1990 | PROCTER & GAMBLE COMPANY, THE, | Sustained release compositions for treating periodontol disease |
5133971, | Dec 14 1988 | Personal dental hygiene assembly | |
5135752, | Oct 14 1988 | WATSON LABORATORIES, INC | Buccal dosage form |
5155144, | Oct 29 1990 | FMC CORPORATION A CORP OF DE | Polysaccharide-based porous sheets |
5262164, | Nov 17 1989 | DUMEX-ALPHARMA A S | Sustained release compositions for treating periodontal disease |
5288532, | Aug 28 1990 | CURWOOD, INC | Transferable modifier-containing film |
5364634, | Nov 08 1991 | SOUTHWEST RESEARCH INSTITUTE, A CORP OF TX | Controlled-release PH sensitive capsule and adhesive system and method |
5374457, | Aug 28 1990 | CURWOOD, INC | Transferable modifier-containing film |
5382391, | Aug 28 1990 | CURWOOD, INC | Method for producing transferable modifier-containing film |
5447725, | Jun 11 1993 | The Procter & Gamble Company; Procter & Gamble Company, The | Methods for aiding periodontal tissue regeneration |
5700478, | Aug 19 1994 | Ortho-McNeil Pharmaceutical, Inc | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
5714165, | Sep 20 1990 | The University of Mississippi | Bioadhesive polyethylene glycol ointment for medicaments |
5851551, | Aug 23 1991 | GILLETTE COMPANY, THE | Sustained-release matrices for dental application |
5894017, | Jun 06 1997 | Procter & Gamble Company, The | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
5906814, | Dec 07 1995 | The Andrew Jergens Company | Topical film-forming compositions |
5906834, | Jun 21 1994 | GILLETTE COMPANY, THE | Color changing matrix as wear indicator |
5914118, | Dec 26 1995 | Sanwa Kagaku Kenkyusho Co., Ltd. | Multi-layered drug containing film preparation having powder adhesive thereon |
5958452, | Apr 10 1997 | PURDUE PHARMA L P | Extruded orally administrable opioid formulations |
5965161, | Nov 04 1994 | PURDUE PHARMA L P | Extruded multi-particulates |
5989569, | Jun 06 1997 | Procter & Gamble Company | Delivery system for a tooth whitener using a permanently deformable strip of material |
5998431, | Aug 23 1991 | GILLETTE COMPANY, THE | Sustained-release matrices for dental application |
6045811, | Jun 06 1997 | Procter & Gamble Company, The | Delivery system for an oral care substance using a permanently deformable strip of material |
6068855, | Nov 03 1994 | Euro-Celtique S. A. | Pharmaceutical composition containing a fusible carrier and method for producing the same |
6096328, | Mar 17 1998 | Procter & Gamble Company, The | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
6136297, | Jun 06 1997 | Procter & Gamble Company, The | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
6153210, | Aug 14 1997 | DEMEGEN, INC | Use of locally delivered metal ions for treatment of periodontal disease |
6231957, | May 06 1999 | Intelgenx Corporation | Rapidly disintegrating flavor wafer for flavor enrichment |
6261599, | Nov 04 1994 | PURDUE PHARMA L P | Melt-extruded orally administrable opioid formulations |
6335033, | Nov 04 1994 | PURDUE PHARMA L P | Melt-extrusion multiparticulates |
6375963, | Jun 16 1999 | UNIVERSITY OF MISSISSIPPI, THE; BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM, THE | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
6419906, | Mar 12 2001 | Colgate Palmolive Company; Colgate-Palmolive Company | Strip for whitening tooth surfaces |
6503486, | Mar 12 2001 | Colgate Palmolive Company; Colgate-Palmolive Company | Strip for whitening tooth surfaces |
6514483, | Mar 12 2001 | Colgate Palmolive Company; Colgate-Palmolive Company | Strip for whitening tooth surfaces |
6551579, | Jun 06 1997 | Procter & Gamble Company, The | Delivery systems for a tooth whitener |
6562363, | Sep 26 1997 | NOVEN PHARMACEUTICALS, INC | Bioadhesive compositions and methods for topical administration of active agents |
6566350, | May 23 2000 | SHOWA YAKUHIN KAKO CO , LTD | Minocycline-containing compositions |
6582708, | Jun 28 2000 | Procter & Gamble Company, The | Tooth whitening substance |
6638881, | Dec 23 1999 | Combe Incorporated | Dental adhesive device and method of producing same |
6660292, | Jun 19 2001 | Intelgenx Corporation | Rapidly disintegrating flavored film for precooked foods |
6682721, | Mar 17 2000 | LG Household & Healthcare Ltd. | Patches for teeth whitening |
6689344, | Mar 17 2000 | LG Household & Healthcare Ltd.; LG HOUSEHOLD AND HEALTH CARE, LTD | Patches for teeth whitening |
6706281, | Nov 04 1994 | PURDUE PHARMA L P | Melt-extrusion multiparticulates |
6743442, | Nov 04 1994 | PURDUE PHARMA L P | Melt-extruded orally administrable opioid formulations |
6780401, | Mar 17 2000 | LG Household & Healthcare Ltd. | Patches for teeth whitening |
6860736, | May 23 2003 | Ultradent Products, Inc.; Ultradent Products, INC | Oral treatment devices that include a thin, flexible barrier layer and an endoskeleton treatment or adhesive composition |
6884426, | Jun 06 1997 | The Procter & Gamble Co. | Methods for whitening teeth |
6946142, | Jun 23 2001 | LG HOUSEHOLD AND HEALTH CARE, LTD | Multi-layer patches for teeth whitening |
6949240, | May 23 2002 | Procter & Gamble Company, The | Tooth whitening products |
6964571, | Jan 24 2003 | Ultradent Products, INC | Pre-shaped dental trays and treatment devices and methods that utilize such dental trays |
6981874, | Oct 22 2003 | Ultradent Products, Inc.; Ultradent Products, INC | Dental bleaching compositions and devices having a solid activation adhesive layer or region and bleaching gel layer or region |
6997708, | Oct 22 2003 | Ultradent Products, Inc. | Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto |
7004756, | Jan 24 2003 | Ultradent Products, INC | Pre-shaped dental trays and treatment devices and methods that utilize such dental trays |
7011523, | Oct 22 2003 | Ultradent Products, Inc.; Ultradent Products, INC | Bleaching compositions and devices having a solid adhesive layer and bleaching gel adjacent thereto |
7018622, | Jun 06 1997 | The Procter & Gamble Company | Structures and compositions increasing the stability of peroxide actives |
7040897, | May 23 2003 | Ultradent Products, Inc. | Thin, flexible membrane dental trays and systems and methods utilizing such trays |
7048543, | May 27 2003 | Ultradent Products, Inc.; Ultradent Products, INC | Substantially solid bleaching composition in a tray-like configuration |
7052275, | May 27 2003 | Ultradent Products, Inc. | Kits and methods for bleaching and desensitizing teeth |
7056118, | May 27 2003 | Ultradent Products, Inc. | Compositions and devices having a tray-like configuration for delivering a medicament and methods of manufacturing and using such compositions and devices |
7059857, | May 27 2003 | Ultradent Products, Inc. | Substantially solid desensitizing compositions and devices having a tray-like configuration and methods of manufacturing and using such compositions and devices |
7059858, | Feb 19 2004 | Ultradent Products, Inc.; Ultradent Products, INC; ULTRADENT PRODUCTS, INC , | Universal tray design having anatomical features to enhance fit |
7074042, | May 27 2003 | Ultradent Products, Inc.; Ultradent Products, INC | Tray-like dental bleaching devices having a barrier layer and a substantially solid bleaching composition |
7122199, | Jun 06 1997 | Procter & Gamble Company, The | Methods for whitening teeth |
7132113, | Jun 19 2001 | Intelgenx Corporation | Flavored film |
7192280, | Feb 19 2004 | Ultradent Products, Inc. | Dental bleaching devices having a protective adhesive region |
7247022, | Jan 31 2005 | Ultradent Products, Inc. | Dental tray system with releasable hold inner and outer dental trays |
7264471, | May 05 2004 | Ultradent Products, Inc. | Methods and kits for bleaching teeth while protecting adjacent gingival tissue |
7338664, | Aug 23 1991 | The Gillette Company | Color changing matrix as wear indicator |
7357891, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Process for making an ingestible film |
7410532, | Feb 04 2005 | Tessera, Inc | Method of controlling a fluid flow |
7425292, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
7452209, | May 02 2005 | Ultradent Products, Inc. | Exoskeleton support for placement of a dental treatment strip |
7470397, | Oct 24 2003 | ADHESIVES RESEARCH, INC | Disintegratable films for diagnostic devices |
7481653, | Jan 24 2003 | OraTech LC | Preshaped thin-walled dental trays and methods of manufacturing and using such trays |
7510727, | Nov 04 1994 | PURDUE PHARMA L P | Melt-extrusion multiparticulates |
7532451, | May 18 2004 | Kronos Advanced Technologies, Inc. | Electrostatic fluid acclerator for and a method of controlling fluid flow |
7576067, | Aug 22 2001 | Ionis Pharmaceuticals, Inc | Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption |
7594958, | Jul 03 2002 | Kronos Advanced Technologies, Inc. | Spark management method and device |
7625210, | Aug 09 2004 | Ultradent Products, Inc. | Treatment devices for providing oral treatments and kits and methods that utilize such treatment devices |
7666337, | Apr 11 2002 | AQUESTIVE THERAPEUTICS, INC | Polyethylene oxide-based films and drug delivery systems made therefrom |
7727466, | Oct 24 2003 | Adhesives Research, Inc. | Disintegratable films for diagnostic devices |
7766658, | Nov 30 2004 | ALIGN TECHNOLOGY, INC. | Systems and methods for intra-oral diagnosis |
7785572, | Mar 17 2000 | LG Household and Health Care Ltd. | Method and device for teeth whitening using a dry type adhesive |
7824588, | Oct 12 2001 | MonoSol Rx, LLC | Method of making self-supporting therapeutic active-containing film |
7862802, | Mar 17 2000 | LG HOUSEHOLD & HEALTH CARE LTD. | Patches for teeth whitening |
7910641, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | PH modulated films for delivery of actives |
7947508, | Nov 30 2004 | Align Technology, INC | Systems and methods for intra-oral diagnosis |
7972618, | Sep 20 2006 | AQUESTIVE THERAPEUTICS, INC | Edible water-soluble film containing a foam reducing flavoring agent |
8007277, | Aug 09 2007 | Ultradent Products, Inc. | Non-custom dental treatment trays and mouth guards having improved anatomical features |
8017150, | Apr 11 2002 | AQUESTIVE THERAPEUTICS, INC | Polyethylene oxide-based films and drug delivery systems made therefrom |
8049426, | Feb 04 2005 | Tessera, Inc. | Electrostatic fluid accelerator for controlling a fluid flow |
8075309, | Nov 30 2004 | ALIGN TECHNOLOGY, INC. | Systems and methods for intra-oral drug delivery |
8075872, | Aug 06 2003 | Endo Pharmaceuticals Inc | Abuse-proofed dosage form |
8114383, | Aug 06 2003 | Endo Pharmaceuticals Inc | Abuse-proofed dosage form |
8114384, | Jul 01 2004 | Endo Pharmaceuticals Inc | Process for the production of an abuse-proofed solid dosage form |
8173152, | Mar 24 2006 | Auxilium US Holdings, LLC | Stabilized compositions containing alkaline labile drugs |
8192722, | Aug 06 2003 | Endo Pharmaceuticals Inc | Abuse-proof dosage form |
8202091, | Aug 31 2007 | Ultradent Products, Inc. | Dental treatment trays comprising silicone elastomeric material |
8277215, | Feb 19 2004 | Ultradent Products, Inc. | Universal non-custom dental tray having anatomical features to enhance fit |
8282954, | Dec 15 2008 | AQUESTIVE THERAPEUTICS, INC | Method for manufacturing edible film |
8309060, | Aug 06 2003 | Grunenthal GmbH | Abuse-proofed dosage form |
8323889, | Jul 14 2004 | Endo Pharmaceuticals Inc | Process for the production of an abuse-proofed solid dosage form |
8383152, | Jan 25 2008 | Gruenenthal GmbH | Pharmaceutical dosage form |
8420056, | Nov 20 2003 | Grunenthal GmbH | Abuse-proofed dosage form |
8439674, | Nov 30 2004 | ALIGN TECHNOLOGY, INC. | Systems and methods for intra-oral drug delivery |
8444413, | Aug 25 2006 | Ultradent Products, Inc. | Non-custom dental treatment trays having improved anatomical features |
8465759, | Mar 24 2006 | Auxilium US Holdings, LLC | Process for the preparation of a hot-melt extruded laminate |
8475832, | Aug 07 2009 | INDIVIOR UK LIMITED | Sublingual and buccal film compositions |
8557286, | Apr 20 2000 | EUROCELTIQUE, S A | Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix |
8603514, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
8613285, | Oct 11 2007 | PHILIP MORRIS PRODUCTS S.A. | Extrudable and extruded compositions for delivery of bioactive agents, method of making same and method of using same |
8647314, | Mar 15 2008 | LTS Lohmann Therapie-Systeme AG | Gingival wafer |
8647607, | Mar 17 2000 | LG HOUSEHOLD & HEALTH CARE LTD. | Patches for teeth whitening |
8652378, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
8652446, | Mar 17 2000 | LG HOUSEHOLD & HEALTHCARE LTD | Apparatus and method for whitening teeth |
8663687, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Film compositions for delivery of actives |
8663696, | Oct 19 2007 | AQUESTIVE THERAPEUTICS, INC | Film delivery system for tetrahydrolipstatin |
8685437, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
8721332, | Aug 25 2006 | Ultradent Products, Inc. | Non-custom dental treatment trays having improved anatomical features |
8722086, | Mar 07 2007 | Gruenenthal GmbH | Dosage form with impeded abuse |
8765167, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
8815289, | Aug 25 2006 | PURDUE PHARMA L P ; PURDUE PHARMACEUTICALS L P | Tamper resistant dosage forms |
8821929, | Aug 25 2006 | PURDUE PHARMA L P ; PURDUE PHARMACEUTICALS L P | Tamper resistant dosage forms |
8834925, | Aug 25 2006 | PURDUE PHARMA L P ; PURDUE PHARMACEUTICALS L P | Tamper resistant dosage forms |
8846086, | Aug 25 2006 | PURDUE PHARMA L P ; PURDUE PHARMACEUTICALS L P | Tamper resistant dosage forms |
8883187, | Mar 24 2006 | Auxilium US Holdings, LLC | Stabilized compositions containing alkaline labile drugs |
8894987, | Aug 25 2006 | PURDUE PHARMA L P ; PURDUE PHARMACEUTICALS L P | Tamper resistant dosage forms |
8894988, | Aug 25 2006 | PURDUE PHARMA L P ; PURDUE PHARMACEUTICALS L P | Tamper resistant dosage forms |
8900497, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Process for making a film having a substantially uniform distribution of components |
8900498, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Process for manufacturing a resulting multi-layer pharmaceutical film |
8906277, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Process for manufacturing a resulting pharmaceutical film |
8911719, | Aug 25 2006 | PURDUE PHARMA L P ; PURDUE PHARMACEUTICALS L P | Tamper resistant dosage forms |
8944819, | Nov 10 2004 | Ranir, LLC | Device and method for delivering an oral care agent |
8956160, | Jul 02 2002 | Ranir, LLC | Device and method for delivering an oral care agent |
8974826, | Jun 10 2010 | AQUESTIVE THERAPEUTICS, INC | Nanoparticle film delivery systems |
9084816, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9095614, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9095615, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9101661, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9108340, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Process for manufacturing a resulting multi-layer pharmaceutical film |
9125434, | Oct 11 2007 | PHILIP MORRIS PRODUCTS S A | Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet |
9161917, | May 09 2008 | Gruenenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
9198865, | Jan 19 2006 | Dow Global Technologies LLC | Biologically active composition comprising ethylcellulose |
9364445, | Mar 24 2006 | Auxilium US Holdings, LLC | Stabilized compositions containing alkaline labile drugs |
9486412, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9486413, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9492389, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9492390, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9492391, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9492392, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9492393, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9498410, | Dec 30 2002 | Colgate-Palmolive Company | Oral and personal care compositions and methods |
9545380, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9554976, | Sep 11 2002 | The Procter & Gamble Company | Tooth whitening product |
9579285, | Feb 03 2010 | Gruenenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
9585961, | Oct 24 2003 | Adhesives Research, Inc. | Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
9629807, | Aug 06 2003 | GRÜNENTHAL GMBH | Abuse-proofed dosage form |
9636303, | Sep 02 2010 | Gruenenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
9642850, | Feb 24 1997 | PURDUE PHARMA L.P. | Method of providing sustained analgesia with buprenorphine |
9655853, | Feb 28 2012 | GRÜNENTHAL GMBH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
9675610, | Jun 17 2002 | GRÜNENTHAL GMBH | Abuse-proofed dosage form |
9687454, | Aug 07 2009 | INDIVIOR UK LIMITED | Sublingual and buccal film compositions |
9717577, | Feb 19 2004 | Ultradent Products, Inc. | Non-custom dental tray having anatomical cuspid-bicuspid cuts and/or V or U-shaped indentation in bottom wall |
9717682, | Dec 08 2009 | Intelgenx Corporation | Solid oral film dosage forms and methods for making same |
9737490, | May 29 2013 | GRÜNENTHAL GMBH | Tamper resistant dosage form with bimodal release profile |
9750701, | Jan 25 2008 | GRÜNENTHAL GMBH | Pharmaceutical dosage form |
9763886, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9763933, | Aug 25 2006 | PURDUE PHARMA L.P. | Tamper resistant dosage forms |
9770416, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9770417, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9775808, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9775809, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9775810, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9775811, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9775812, | Aug 25 2006 | PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P. | Tamper resistant dosage forms |
9801837, | May 08 2006 | The University of Mississippi | Stabilized formulation of triamcinolone acetonide |
9827172, | Dec 30 2002 | Colgate-Palmolive Company | Dentifrice containing functional film flakes |
9855221, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
9855263, | Apr 24 2015 | GRÜNENTHAL GMBH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
9867786, | Mar 24 2006 | Auxilium US Holdings, LLC | Stabilized compositions containing alkaline labile drugs |
9872835, | May 26 2014 | GRÜNENTHAL GMBH | Multiparticles safeguarded against ethanolic dose-dumping |
9913814, | May 12 2014 | GRÜNENTHAL GMBH | Tamper resistant immediate release capsule formulation comprising tapentadol |
9918909, | Dec 30 2002 | Colgate-Palmolive Company | Oral and personal care compositions and methods |
9925146, | Jul 22 2009 | GRÜNENTHAL GMBH | Oxidation-stabilized tamper-resistant dosage form |
9931305, | Oct 12 2001 | AQUESTIVE THERAPEUTICS, INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
9937123, | Oct 24 2003 | Adhesives Research, Inc. | Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
9949809, | Aug 31 2007 | Ultradent Products, INC | Dental treatment devices comprising silicone-like elastomeric material |
Patent | Priority | Assignee | Title |
4292299, | Nov 06 1978 | Teijin Limited | Slow-releasing medical preparation to be administered by adhering to a wet mucous surface |
4421738, | Jul 31 1979 | Eisai Co., Ltd. | Sugar-coated tablet containing fat-soluble pharmaceutical material |
4517173, | Sep 26 1980 | Nippon Soda Co. Ltd. | Mucous membrane-adhering film preparation and process for its preparation |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Nov 16 1988 | Johnson & Johnson Consumer Products, Inc. | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Jun 03 1991 | M173: Payment of Maintenance Fee, 4th Year, PL 97-247. |
May 25 1995 | M184: Payment of Maintenance Fee, 8th Year, Large Entity. |
May 03 1999 | M185: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Oct 17 1992 | 4 years fee payment window open |
Apr 17 1993 | 6 months grace period start (w surcharge) |
Oct 17 1993 | patent expiry (for year 4) |
Oct 17 1995 | 2 years to revive unintentionally abandoned end. (for year 4) |
Oct 17 1996 | 8 years fee payment window open |
Apr 17 1997 | 6 months grace period start (w surcharge) |
Oct 17 1997 | patent expiry (for year 8) |
Oct 17 1999 | 2 years to revive unintentionally abandoned end. (for year 8) |
Oct 17 2000 | 12 years fee payment window open |
Apr 17 2001 | 6 months grace period start (w surcharge) |
Oct 17 2001 | patent expiry (for year 12) |
Oct 17 2003 | 2 years to revive unintentionally abandoned end. (for year 12) |